Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.
apolipoprotein B mRNA-editing catalytic polypeptide-like 3 family member (APOBEC3)
core-binding factor beta (CBFβ)
dominant negative mutant
human immunodeficiency virus (HIV)
viral infectivity factor (Vif)
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
14 09 2022
14 09 2022
Historique:
pubmed:
12
8
2022
medline:
17
9
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Apolipoprotein B mRNA-editing catalytic polypeptide-like 3 family members (APOBEC3s) are host restriction factors that inhibit viral replication. Viral infectivity factor (Vif), a human immunodeficiency virus type 1 (HIV-1) accessory protein, mediates the degradation of APOBEC3s by forming the Vif-E3 complex, in which core-binding factor beta (CBFβ) is an essential molecular chaperone. Here, we screened nonfunctional Vif mutants with high affinity for CBFβ to inhibit HIV-1 in a dominant negative manner. We applied the yeast surface display technology to express Vif random mutant libraries, and mutants showing high CBFβ affinity were screened using flow cytometry. Most of the screened Vif mutants containing random mutations of different frequencies were able to rescue APOBEC3G (A3G). In the subsequent screening, three of the mutants restricted HIV-1, recovered G-to-A hypermutation, and rescued APOBEC3s. Among them, Vif-6M showed a cross-protection effect toward APOBEC3C, APOBEC3F, and African green monkey A3G. Stable expression of Vif-6M in T lymphocytes inhibited the viral replication in newly HIV-1-infected cells and the chronically infected cell line H9/HXB2. Furthermore, the expression of Vif-6M provided a survival advantage to T lymphocytes infected with HIV-1. These results suggest that dominant negative Vif mutants acting on the Vif-CBFβ target potently restrict HIV-1.
Identifiants
pubmed: 35950859
doi: 10.1128/jvi.00555-22
pmc: PMC9472641
doi:
Substances chimiques
Core Binding Factor beta Subunit
0
vif Gene Products, Human Immunodeficiency Virus
0
vif protein, Human immunodeficiency virus 1
0
APOBEC Deaminases
EC 3.5.4.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0055522Références
Mol Ther. 2003 Sep;8(3):475-84
pubmed: 12946321
J Exp Med. 1992 Oct 1;176(4):1197-201
pubmed: 1402661
Nature. 2011 Dec 21;481(7381):371-5
pubmed: 22190037
Microbiol Mol Biol Rev. 2016 Jun 29;80(3):679-731
pubmed: 27357278
J Virol. 2009 Sep;83(17):8544-52
pubmed: 19535447
J Virol. 2009 Sep;83(17):8536-43
pubmed: 19515760
J Virol. 2011 Mar;85(5):2254-65
pubmed: 21159874
J Virol. 2010 May;84(10):5250-9
pubmed: 20219927
Adv Pharmacol. 2000;48:75-120
pubmed: 10987089
Nature. 2002 Aug 8;418(6898):646-50
pubmed: 12167863
Mol Cell. 2003 Sep;12(3):591-601
pubmed: 14527406
Expert Opin Ther Targets. 2015 Feb;19(2):245-63
pubmed: 25388088
J Virol. 1992 Nov;66(11):6489-95
pubmed: 1357189
Retrovirology. 2017 Mar 17;14(1):19
pubmed: 28302150
J Virol. 2014 Mar;88(5):2555-63
pubmed: 24352440
J Virol. 2020 Mar 17;94(7):
pubmed: 31941780
J Virol. 2012 May;86(10):5497-507
pubmed: 22379088
Nature. 2014 Jan 9;505(7482):229-33
pubmed: 24402281
AIDS Res Hum Retroviruses. 2012 Dec;28(12):1543-51
pubmed: 22725134
J Biol Chem. 2016 Nov 25;291(48):24892-24899
pubmed: 27758855
Curr HIV Res. 2008 Mar;6(2):91-9
pubmed: 18336256
PLoS Pathog. 2015 Jan 15;11(1):e1004609
pubmed: 25590131
J Virol. 2010 May;84(10):5201-11
pubmed: 20219919
Cell Rep. 2015 May 26;11(8):1236-50
pubmed: 25981045
Methods Mol Biol. 2015;1319:155-75
pubmed: 26060074
J Virol. 2014 May;88(9):4839-52
pubmed: 24522927
J Biol Chem. 2004 Aug 13;279(33):34083-6
pubmed: 15215254
J Virol. 2014 Mar;88(6):3309-19
pubmed: 24390320
Trends Mol Med. 2018 May;24(5):507-520
pubmed: 29609878
Science. 2003 May 16;300(5622):1112
pubmed: 12750511
PLoS Pathog. 2010 Jun 03;6(6):e1000925
pubmed: 20532212
Mol Cell. 2013 Feb 21;49(4):632-44
pubmed: 23333304
J Virol. 2014 Oct;88(20):12112-22
pubmed: 25122780
Virology. 2014 Jan 20;449:82-7
pubmed: 24418540
J Virol. 2019 Oct 15;93(21):
pubmed: 31413124
Science. 2003 Nov 7;302(5647):1056-60
pubmed: 14564014
Cell. 1989 Jul 14;58(1):205-14
pubmed: 2752419
Virology. 2006 Jun 5;349(2):290-9
pubmed: 16530799
Mol Ther Nucleic Acids. 2018 Dec 7;13:514-533
pubmed: 30388625
Virology. 2008 Jul 20;377(1):49-53
pubmed: 18499212
Blood. 2009 Apr 9;113(15):3443-52
pubmed: 19211937
Nature. 2011 Dec 21;481(7381):376-9
pubmed: 22190036
Hum Gene Ther. 2005 Sep;16(9):1065-74
pubmed: 16149905
J Biol Chem. 2020 Oct 23;295(43):14592-14605
pubmed: 32817167
Curr Top Microbiol Immunol. 2015;389:1-29
pubmed: 25821102
Biophys J. 2009 Feb;96(3):964-73
pubmed: 19186134
Retrovirology. 2007 Jul 16;4:48
pubmed: 17631688
Nucleic Acids Res. 2007;35(21):7096-108
pubmed: 17942420
J Virol. 1997 Feb;71(2):1443-52
pubmed: 8995670
Hum Gene Ther. 2013 Mar;24(3):270-82
pubmed: 23298160